JPET xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on October 11, 2007; DOI: 10.1124/jpet.107.130435


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
jpet.107.130435v1
jpet.107.130435v2
324/1/206    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hu, X. E.
Right arrow Articles by Reizes, O.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hu, X. E.
Right arrow Articles by Reizes, O.


Received for publication August 17, 2007.
Revised October 8, 2007.
Accepted for publication October 9, 2007.

Small molecule melanin concentrating hormone-1 receptor antagonists require brain penetration for inhibition of food intake and reduction in body weight

X. Eric Hu 1, John A. Wos 2, Martin E. Dowty 3, Paula M. Suchanek 2, Wei Ji 2, James B. Chambers 1, Stephen C. Benoit 1, Deborah J. Clegg 1, Ofer Reizes 4*

1 University of Cincinnati 2 Procter & Gamble Pharmaceuticals, Inc. 3 Prizer, Inc. 4 Cleveland Clinic Foundation

* Address correspondence to: E-mail: reizeso{at}ccf.org

Abstract

The melanin concentrating hormone-1 receptor (MCH1R) is a G-protein coupled receptor, expressed in the brain and peripheral tissues that regulates energy storage and body weight. Here we focused on discovery of the mechanism and site of action for a small molecule MCH1R antagonist, which yields weight loss in a mouse model of human obesity. MCH1R is expressed throughout the brain, but also found in peripheral tissues known to regulate fat storage and utilization, e.g. skeletal muscle and adipose tissue. Previous studies of MCH1R antagonist studies have not delineated the site that is critical for mediating the anorexigenic and weight reducing actions. In this study, we evaluated the role of the brain and peripheral tissue receptors. We developed a novel non-brain permeable MCH antagonist analog with a carboxylic acid moiety to specifically test the site of action. Based on in vitro and in vivo assays the analog is not able to cross the blood brain barrier and does not lead to inhibition of food intake and reduced body weight. The data clearly demonstrate that MCH1R antagonists need access to the brain in order to reduce body weight and fat mass. The brain permeable MCH1R antagonist leads to significant reduction in body weight and fat mass in diet induced obese mice. The effect is dose dependent and appears to be partially driven by a reduction in food intake. Finally, these studies show the utility of a medicinal chemistry approach to address an important biological and pharmacological question.


Key words: brain permeability, fat, food intake, medicinal chemistry, melanin concentrating hormone, obesity





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics.